Journal
JOURNAL OF HUMAN HYPERTENSION
Volume 14, Issue 9, Pages 581-585Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.jhh.1001102
Keywords
angiotensin II; platelet shape change; losartan; serotonin
Categories
Ask authors/readers for more resources
Platelet shape change (PSC) is an early phase of platelet activation that precedes platelet aggregation. This phase of platelet activation is essentially aspirin resistant. PSC was monitored, by measuring the median platelet volume (MPV) using a high resolution channelyser, Angiotensin (Ang) II, added in vitro, caused a significant (P = 0.004) increase in MPV in platelet rich plasma prepared from healthy subjects (n = 14). This increase in MPV was marked (> 0.40 fl) in 57% (n = 8) of these subjects and was significantly inhibited (P < 0.008) by losartan (a selective Ang II antagonist) at concentrations similar to those achieved in the circulation during treatment. Ang II also significantly enhanced sub-maximal PSC induced by ADP and serotonin in all subjects tested, Losartan significantly (n = 9; P < 0.001) inhibited U46619 (a thromboxane A(2) analogue)-induced PSC, These findings suggest that losartan, in addition to its blood pressure lowering action, has antiplatelet activity, This property may be clinically relevant because of the increased risk of vascular events in hypertensive patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available